CAR-T-cell treatment is thought to be one of the most promising therapies in development for the treatment of myeloma. There are several ongoing clinical trials evaluating the safety and efficacy of CAR-T-cells, and some of the studies with very encouraging results.
To provide an overview of the main highlights on CAR-T-cells, the European Society for Blood and Marrow Transplantation (EBMT) and the European Haematology Association (EHA) will host the 3rd edition of the European CAR T-cell Meeting. From 4 to 6 February 2021, European experts on CAR-T will discuss the ongoing and rising preclinical and clinical activities in Europe. According to the EBMT registry more than a 1.000 patients have been treated with CAR T-cell. Therefore, it is expected that researchers will discuss expectations surrounding regulatory approval and market access of CAR-T-cell products in Europe.
Find more information and register to attend this congress here.
MPE and CARAMBA at 3rd European CAR T-cell Meeting
With the aim of representing the patient perspective and highlighting the crucial role of patient organisations in the development process of CAR-T treatments, Myeloma Patients Europe (MPE) will be attending the 3rd European CAR T-cell Meeting. The CEO of MPE, Ananda Plate, will be participating in the session “EU grants and projects” (Saturday, 6 February from 11.00 to 12.00 CET) and sharing the MPE role within the Horizon 2020 project CARAMBA. This project is investigating a CAR-T-cell drug that targets the SLAMF7 protein that is commonly expressed on the surface of myeloma cells. Other CARAMBA project partners such as Dr Michael Hudecek, Dr Monica Casucci, Dr Hermann Einsele, Dr Halvard Bönig and Dr Ibrahim Yakoub-Agha will be also participating in this meeting.
Have a look at the preliminary programme here.
For further information on CARAMBA, please click here or visit the Horizon2020 website: https://www.caramba-cart.eu